Top Quality Chemical Peptides Cilengitide CAS 188968-51-6

Product Details
Customization: Available
Powder: Yes
Customized: Customized
Still deciding? Get samples of US$ 200/g
Request Sample
Manufacturer/Factory, Trading Company
Gold Member Since 2023

Suppliers with verified business licenses

Audited Supplier

Audited by an independent third-party inspection agency

  • Top Quality Chemical Peptides Cilengitide CAS 188968-51-6
  • Top Quality Chemical Peptides Cilengitide CAS 188968-51-6
  • Top Quality Chemical Peptides Cilengitide CAS 188968-51-6
  • Top Quality Chemical Peptides Cilengitide CAS 188968-51-6
  • Top Quality Chemical Peptides Cilengitide CAS 188968-51-6
  • Top Quality Chemical Peptides Cilengitide CAS 188968-51-6
Find Similar Products
  • Overview
  • Product Description
  • Application
  • Our Advantages
  • Company Profile
Overview

Basic Info.

Model NO.
LM-Cilengitide
Suitable for
Elderly, Adult
State
Powder
Purity
>98%
Product Name
Cilengitide
Appearance
White Powder
CAS
188968-51-6
Mf
C27h40n8o7
MW
588.65
Test Method
HPLC
MOQ
1 G
Sample
Available
Storage
Cool Dry Area
Certificate
COA/MSDS
Payment
Tt, Paypal, Western Union and So on
Packaging
1kg/Bag 25kg/Drum
Transport Package
1kg/Bag 25kg/Drum
Specification
98%
Trademark
Bpanda
Origin
China
Production Capacity
10tons/Year

Product Description

Top Quality Chemical Peptides Cilengitide CAS 188968-51-6
   
                              Top Quality Chemical Peptides Cilengitide CAS 188968-51-6
Product Description

 

Top Quality Chemical Peptides Cilengitide CAS 188968-51-6

Product  Name: Cilengitide
Cas No: 188968-51-6
Formula: C27H40N8O7
Molecular:588.65
Sequence: Cyclo(L-arginylglycyl-L-alpha-aspartyl-D-phenylalanyl-N-methyl-L-valyl)
Purity:98%
Appearance: white powder
Source: synthetic


Cilengitide is a cyclized pentapeptide peptidomimetic designed to compete for the arginine-glycine-aspartic acid (RGD) peptide sequence that regulates integrin-ligand binding. Cilengitide selectively and potently blocks the ligation of theαvβ3 andαvβ5 integrins to provisional matrix proteins such as vitronectin, fibronectin, fibrinogen, von Willebrand factor, osteopontin, and others. Cilegitide inhibits angiogenesis in vitro. 10 μM Cilengitide completely inhibits attachment of BAE, BME and HUVE cells on vitronectin and fibronectin. Cilengitide inhibits in vitro angiogenesis of BAE cells on three-dimensional collagen and fibrin gels pretreated with FGF-2(or VEGF-A) with IC50 of 15 μM and 8 μM, 4 μM and 3 μM, respectively.Cilengitide blocks proliferation and induces apoptosis of endothelial cells as well as differentiation of human endothelial precursor cells (EPCs). 50 μg/mL Cilengitide completely inhibits the proliferation of human microvascular endothelial cell line HMEC-1 and leads to apoptosis in ~30% cells. 1.0 μM Cilengitide treating for 9 days inhibits the proliferation of EPCs by nearly 40%. 1 μM Cilengitide inhibits the differentiation of EPCs by more than 80% at 14 days. Cilengitide inhibits adhesion and induces apoptosis of tumor cells. 25 μg/mL Cilengitide causes detachment of DAOY cells (medulloblastoma) and U87MG cells (glioblastoma) from vitronectin and tenascin by more than 60%. 25 μg/mL Cilengitide induces a nearly 50% apoptosis rate of these cells

 
Application


Cilengitide is activity against tumor growth and angiogenesis as single-agent. 100 μg Cilengitide induces a significant decrease in the number of CD 31+ vessels seen in tumors (2/high-power field) compared with control tumors (56/high-power field). 100 μg Cilengitide increases cellular apoptosis in the brain tumors of animals (2.2% apoptotic cells/high-power field) compared with those receiving the inactive peptide (1.7% cells/high-power field). Cilengitide treatment results in prolonged survival of the mice bearing melanoma xenografts M21 compared with control treatment group. (36.5 vs 17.3 days). Cilengitide can augment the therapeutic benefit associated with cytotoxic agents including chemotherapy and radiation therapy in tumor models. Cilengitide (250 mg/dose) alone does not alter tumor growth of breast cancer xenografts when compared with untreated mice, but combined modality RIT (CMRIT) using RIT and six doses of Cilengitide (250 mg/dose) increases efficacy of treatment, with the cure rate for mice that receives only RIT increasing from 15 to 53%. CMRIT significantly increases apoptosis of tumor and endothelial cells 5 days, and decreases tumor proliferation.

Our Advantages

We have overseas warehouses in California, New York,New Laredo Mexico, Vancouver Canada, Amsterdam Netherlands, Spain,and Melbourne Australia. Overseas warehouses can provide some of the best-selling products. We look forward to the cooperation of local powerful distributors and factories. 

We guarantee that 100% of the packages you order pass the customs of the United States, Mexico, Canada, the 27 EU countries, the United Kingdom, Australia, and Southeast Asian countries. We have a strong customs clearance agency in these countries, and our customs clearance company will clear your parcel without any customs issues, sometimes even 1000 kg. On-site service DDP service. In order to ensure 100% receipt of your package, if there is any customs issue, we promise to reissue it again free of charge. Let you experience our strong transportation and customs clearance capabilities

Company Profile

 

Top Quality Chemical Peptides Cilengitide CAS 188968-51-6
Top Quality Chemical Peptides Cilengitide CAS 188968-51-6
Top Quality Chemical Peptides Cilengitide CAS 188968-51-6
Top Quality Chemical Peptides Cilengitide CAS 188968-51-6
Top Quality Chemical Peptides Cilengitide CAS 188968-51-6Top Quality Chemical Peptides Cilengitide CAS 188968-51-6Top Quality Chemical Peptides Cilengitide CAS 188968-51-6
Top Quality Chemical Peptides Cilengitide CAS 188968-51-6

Send your message to this supplier

*From:
*To:
*Message:

Enter between 20 to 4,000 characters.

This is not what you are looking for? Post a Sourcing Request Now
Contact Supplier